Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand visibility and attributed challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - Consequently, the positive statements made by the defendants about the company's business, operations, and prospects were materially false, misleading, or lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=148835&from=4CLAS ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST). Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=148453&fro ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that negatively impacted the company's financial performance during the specified class period [1][3]. Group 1: Allegations - The complaint alleges that West Pharmaceutical Services issued materially false and misleading statements regarding customer demand visibility and attributed operational challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 16, 2023, to February 12, 2025, with a deadline for shareholders to register for the class action set for July 7, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, and there is no cost or obligation to participate [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring companies adhere to responsible business practices [5].

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147732&from=4 CLA ...

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a membe ...

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly making false statements and failing to disclose significant issues affecting its financial performance during the Class Period from February 16, 2023, to February 12, 2025 [1][3]. Group 1: Allegations of Misleading Statements - The lawsuit claims that West Pharmaceutical misrepresented its visibility into customer demand and attributed challenges to temporary COVID-related product destocking, while it was actually facing ongoing destocking in its High-Value Products portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, negatively impacted profit margins due to operational inefficiencies [3]. - The lawsuit also points out that these margin pressures could lead to costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. Group 2: Financial Forecast and Market Reaction - On February 13, 2025, West Pharmaceutical issued a revenue forecast for 2025 between $2.88 billion and $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to challenges in Contract Manufacturing, including the loss of two major continuous glucose monitoring customers transitioning to in-house manufacturing [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=147325&from=4 CLAS ...